Abstract
Chronic lymphocytic leukemia is an extremely heterogeneous disease and prognostic factors such as chromosomal abnormalities are important predictors of time to first treatment and survival. Trisomy 12 is the second most frequent aberration detected by fluorescence in situ hybridization at the time of diagnosis (10-25%), and it confers an intermediate prognostic risk, with a median time to first treatment of 33 months and a median overall survival of 114 months. Here, we review the unique morphological, immunophenotypic, and genetic characteristics of patients with chronic lymphocytic leukemia and trisomy 12. These patients carry a significantly higher expression of CD19, CD22, CD20, CD79b, CD24, CD27, CD38, CD49d, sIgM, sIgk, and sIgλ and lower expression of CD43 compared with patients with normal karyotype. Circulating cells show increased expression of the integrins CD11b, CD18, CD29, and ITGB7, and of the adhesion molecule CD323. Patients with chronic lymphocytic leukemia and trisomy 12 frequently have unmutated IGHV, ZAP-70 positivity, and closely homologous stereotyped B-cell receptors. They rarely show TP53 mutations but frequently have NOTCH1 mutations, which can be identified in up to 40% of those with a rapidly progres...Continue Reading
Citations
Jun 30, 2019·Cancers·Francesco AutoreLuca Laurenti
May 3, 2019·Journal of Cellular Physiology·Tina VosoughiNajmaldin Saki
Mar 14, 2020·Blood Advances·Agnieszka MałeckaGunhild Trøen
Jul 18, 2020·British Journal of Haematology·Liron Barnea SlonimQing Chen
Jun 25, 2020·British Journal of Haematology·Gian Matteo RigolinAntonio Cuneo
Sep 15, 2020·Exploration of Targeted Anti-tumor Therapy·Rachael ArthurGraham Packham
Jun 18, 2020·Genetics in Medicine : Official Journal of the American College of Medical Genetics·UNKNOWN eMERGE Clinical Annotation Working Group
Dec 1, 2020·Expert Review of Hematology·Marc Sorigue
Dec 15, 2020·International Journal of Laboratory Hematology·Dina S SolimanAhmad Al-Sabbagh
Jan 18, 2021·International Journal of Laboratory Hematology·Arambam GautamNeelam Varma
Feb 20, 2021·PloS One·Sana Dlawar Jalal
Feb 20, 2021·Cancer Management and Research·Paulina StefaniukMonika Podhorecka
May 28, 2021·Leukemia Research Reports·Fady Gh HaddadChantal Farra
Jul 1, 2021·BMC Medical Genomics·Ti'ara L GriffenJames W Lillard
Aug 13, 2021·The Indian Journal of Medical Research·Dhanlaxmi ShettyP G Subramanian